A wave of interest in trending weight loss drugs, fueled by headline-dominating celebrity slim-downs, is causing some employers to see their healthcare costs skyrocket. Now, leaders are turning to benefit providers, advisers and innovators to help them quell costs and offer alternative solutions to treat obesity and manage weight.
The medications in question, including Ozempic, Wegovy and Mounjaro, are part of a class of drugs known as GLP-1s, which are used to treat diabetes and can also help drive weight loss, in some cases supporting the loss of 15% (or more) of body weight.
